119 related articles for article (PubMed ID: 9406598)
1. Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
Wilkerson WW; Dax S; Cheatham WW
J Med Chem; 1997 Dec; 40(25):4079-88. PubMed ID: 9406598
[TBL] [Abstract][Full Text] [Related]
2. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
[TBL] [Abstract][Full Text] [Related]
3. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
[TBL] [Abstract][Full Text] [Related]
4. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.
Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP
J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627
[TBL] [Abstract][Full Text] [Related]
5. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
6. Use of N-methylpiperazine for the preparation of piperazine-based unsymmetrical bis-ureas as anti-HIV agents.
El-Faham A; Armand-Ugón M; Esté JA; Albericio F
ChemMedChem; 2008 Jul; 3(7):1034-7. PubMed ID: 18383064
[No Abstract] [Full Text] [Related]
7. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
9. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
[TBL] [Abstract][Full Text] [Related]
11. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Spaltenstein A; Almond MR; Bock WJ; Cleary DG; Furfine ES; Hazen RJ; Kazmierski WM; Salituro FG; Tung RD; Wright LL
Bioorg Med Chem Lett; 2000 Jun; 10(11):1159-62. PubMed ID: 10866371
[TBL] [Abstract][Full Text] [Related]
13. [Current status of HIV protease inhibitors].
Yang QG; He XC; Bai DL
Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778
[No Abstract] [Full Text] [Related]
14. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Rodgers JD; Lam PY; Johnson BL; Wang H; Li R; Ru Y; Ko SS; Seitz SP; Trainor GL; Anderson PS; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Wright MR; Chang CH; Erickson-Viitanen S
Chem Biol; 1998 Oct; 5(10):597-608. PubMed ID: 9818151
[TBL] [Abstract][Full Text] [Related]
15. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Debnath AK
J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
[TBL] [Abstract][Full Text] [Related]
17. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
[TBL] [Abstract][Full Text] [Related]
18. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
Garg R; Bhhatarai B
Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
[TBL] [Abstract][Full Text] [Related]
19. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
[TBL] [Abstract][Full Text] [Related]
20. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
